Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Full Title

A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Purpose of Study

The purpose of this research study is to find out whether GSK1278863 compared to a placebo (an inactive substance) can reduce some of the complications that can happen from your planned surgery.  The complications that could be reduced are due to low blood flow to the brain, heart, or kidneys, which could cause stroke, heart attack, or kidney failure. 

Sponsor: GlaxoSmithKline 

Local Principal Investigator: Thomas G. Gleason, MD

Division(s)

Research Type

Contact Information

Chrissy Butler, RN
412-647-2782
butlercm@upmc.edu

Eligibility

Patients that have a thoracic aortic aneurysm and are scheduled to have elective surgery to repair it.

For more information, visit ClinicalTrials.gov link.